Loading people...
Arunas Chesonis is the Managing Partner at Safar Partners, an early-stage technology venture capital firm based in Cambridge, Massachusetts. Before transitioning to venture capital, he served as the Founder, Chairman, and CEO of PAETEC Communications, scaling the telecommunications enterprise to over $1.5 billion in annual revenue prior to its $1.06 billion acquisition. He subsequently established the family office Cranberry Capital and began actively funding early-stage environmental, renewable energy, and advanced materials startups across the United States. At Safar Partners, Chesonis now oversees a portfolio of more than 75 companies and manages over $1 billion in assets, directing capital toward complex, science-driven enterprises. Drawing on his engineering education from the Massachusetts Institute of Technology, his current investment strategy focuses on commercializing deep tech, cleantech, and life sciences research spinning out of MIT and Harvard.
Arunas Chesonis stands as a prominent figure in the venture capital landscape, serving as the Managing Partner at Safar Partners. In this pivotal role, he spearheads the firm's strategic direction and investment initiatives, focusing on groundbreaking technologies with the potential to redefine industries. Safar Partners, under Chesonis's leadership, is dedicated to backing early-stage companies that emerge from cutting-edge research, particularly those in deep tech, advanced materials, artificial intelligence, robotics, and life sciences.
Chesonis's investment philosophy is deeply rooted in his extensive entrepreneurial background. Before co-founding Safar Partners, he built a remarkable career as a serial entrepreneur and executive, demonstrating a consistent ability to identify market needs and build successful enterprises. A notable achievement includes his role as co-founder, Chairman, and CEO of EndoVascular Technologies (EVT), a medical device company that pioneered minimally invasive surgical techniques. EVT's innovative approach led to its successful acquisition by Johnson & Johnson, marking a significant milestone in Chesonis's career.
His entrepreneurial spirit also extended into the biotechnology sector, where he co-founded, chaired, and served as CEO of ArQule, Inc. (NASDAQ: ARQL). ArQule became a publicly traded company focused on developing novel cancer therapies, further solidifying Chesonis's reputation as a visionary leader capable of navigating complex scientific and business landscapes. Additionally, he co-founded and led MedVenture Associates, a venture capital firm specializing in medical technology, and co-founded Sweetwater Medical. His experience also includes leading the Chesonis Family Office as its Chairman and CEO.
At Safar Partners, Arunas Chesonis leverages this wealth of experience to guide portfolio companies through critical growth stages, from initial concept to market penetration. He is particularly adept at recognizing the commercial viability of complex scientific innovations, bridging the gap between academic research and real-world application. His strategic insights and hands-on approach provide invaluable support to founders, helping them overcome challenges and accelerate their development. Chesonis's commitment to fostering innovation and his proven track record of success make him a highly respected and influential investor in the global technology and life sciences sectors.
Arunas Chesonis is the Managing Partner at Safar Partners, a venture capital firm. He is a highly experienced entrepreneur and investor with a strong background in founding and leading successful technology and life sciences companies.
Arunas Chesonis, through Safar Partners, invests in disruptive technologies, including deep tech, advanced materials, artificial intelligence, robotics, and life sciences. He focuses on early-stage ventures with significant growth potential, often originating from academic research.
Arunas Chesonis works as the Managing Partner at Safar Partners, a venture capital firm. He also serves as the Chairman and CEO of the Chesonis Family Office, reflecting his continued involvement in strategic investment and business leadership.
